Search

Your search keyword '"Hanly, J. G."' showing total 209 results
Start Over Author "Hanly, J. G."
209 results on '"Hanly, J. G."'

3. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus

Author

Hanly, J G, Urowitz, M B, Su, L, Bae, S-C, Gordon, C, Clarke, A, Bernatsky, S, Vasudevan, A, Isenberg, D, Rahman, A, Wallace, D J, Fortin, P R, Gladman, D, Romero-Dirz, J, Sanchez-Guerrero, J, Dooley, M A, Bruce, I, Steinsson, K, Khamashta, M, Manzi, S, Ramsey-Goldman, R, Sturfelt, G, Nived, O, van Vollenhoven, R, Ramos-Casals, M, Aranow, C, Mackay, M, Kalunian, K, Alarcón, G S, Fessler, B J, Ruiz-Irastorza, G, Petri, M, Lim, S, Kamen, D, Peschken, C, Farewell, V, Thompson, K, Theriault, C, and Merrill, J T

Published
2011
Full Text
View/download PDF

4. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus

Author

Hanly, J G, Urowitz, M B, Jackson, D, Bae, S C, Gordon, C, Wallace, D J, Clarke, A, Bernatsky, S, Vasudevan, A, Isenberg, D, Rahman, A, Sanchez-Guerrero, J, Romero-Diaz, J, Merrill, J T, Fortin, P R, Gladman, D D, Bruce, I N, Steinsson, K, Khamashta, M, Alarcón, G S, Fessler, B, Petri, M, Manzi, S, Nived, O, Sturfelt, G, Ramsey-Goldman, R, Dooley, M A, Aranow, C, Van Vollenhoven, R, Ramos-Casals, M, Zoma, A, Kalunian, K, and Farewell, V

Published
2011
Full Text
View/download PDF

6. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

Author

Bertsias, G K, Ioannidis, J P A, Aringer, M, Bollen, E, Bombardieri, S, Bruce, I N, Cervera, R, Dalakas, M, Doria, A, Hanly, J G, Huizinga, T W J, Isenberg, D, Kallenberg, C, Piette, J C, Schneider, M, Scolding, N, Smolen, J, Stara, A, Tassiulas, I, Tektonidou, M, Tincani, A, van Buchem, M A, van Vollenhoven, R, Ward, M, Gordon, C, and Boumpas, D T

Published
2010
Full Text
View/download PDF

7. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

Author

Hanly, J G, Urowitz, M B, Su, L, Bae, S C, Gordon, C, Wallace, D J, Clarke, A, Bernatsky, S, Isenberg, D, Rahman, A, Alarcón, G S, Gladman, D D, Fortin, P R, Sanchez-Guerrero, J, Romero-Diaz, J, Merrill, J T, Ginzler, E, Bruce, I N, Steinsson, K, Khamashta, M, Petri, M, Manzi, S, Dooley, M A, Ramsey-Goldman, R, Van Vollenhoven, R, Nived, O, Sturfelt, G, Aranow, C, Kalunian, K, Ramos-Casals, M, Zoma, A, Douglas, J, Thompson, K, and Farewell, V

Published
2010
Full Text
View/download PDF

8. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study

Author

Hanly, J. G., Urowitz, M. B., Siannis, F., Farewell, V., Gordon, C., Bae, S. C., Isenberg, D., Dooley, M. A., Clarke, A., Bernatsky, S., Gladman, D., Fortin, P. R., Manzi, S., Steinsson, K., Bruce, I. N., Ginzler, E., Aranow, C., Wallace, D. J., Ramsey-Goldman, R., van Vollenhoven, R., Sturfelt, G., Nived, O., Sanchez-Guerrero, J., Alarcón, G. S., Petri, M., Khamashta, M., Zoma, A., Font, J., Kalunian, K., Douglas, J., Qi, Q., Thompson, K., and Merrill, J. T.

Published
2008

9. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

Author

Hanly, J. G., Urowitz, M. B., Sanchez-Guerrero, J., Bae, S. C., Gordon, C., Wallace, D. J., Isenberg, D., Alarcón, G. S., Clarke, A., Bernatsky, S., Merrill, J. T., Petri, M., Dooley, M. A., Gladman, D., Fortin, P. R., Steinsson, K., Bruce, I., Manzi, S., Khamashta, M., Zoma, A., Aranow, C., Ginzler, E., Van Vollenhoven, R., Font, J., Sturfelt, G., Nived, O., Ramsey-Goldman, R., Kalunian, K., Douglas, J., Thompson, K., and Farewell, V.

Published
2007

14. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients

Author

Choi, M Y, primary, Clarke, A E, additional, St Pierre, Y, additional, Hanly, J G, additional, Urowitz, M B, additional, Romero-Diaz, J, additional, Gordon, C, additional, Bae, S-C, additional, Bernatsky, S, additional, Wallace, D J, additional, Merrill, J T, additional, Isenberg, D A, additional, Rahman, A, additional, Ginzler, E M, additional, Petri, M, additional, Bruce, I N, additional, Dooley, M A, additional, Fortin, P, additional, Gladman, D D, additional, Sanchez-Guerrero, J, additional, Steinsson, K, additional, Ramsey-Goldman, R, additional, Khamashta, M A, additional, Aranow, C, additional, Alarcón, G S, additional, Manzi, S, additional, Nived, O, additional, Zoma, A A, additional, van Vollenhoven, R F, additional, Ramos-Casals, M, additional, Ruiz-Irastorza, G, additional, Lim, S S, additional, Kalunian, K C, additional, Inanc, M, additional, Kamen, D L, additional, Peschken, C A, additional, Jacobsen, S, additional, Askanase, A, additional, Buyon, J, additional, Mahler, M, additional, and Fritzler, M J, additional

Published
2017
Full Text
View/download PDF

15. Anti-C1q antibodies in systemic lupus erythematosus

Author

Dooley, M A, Gordon, C, Khamashta, M A, Sturfelt, G, Costner, M I, Fang, H, Orbai, A-M, Wallace, D J, Ramsey-Goldman, R, Aranow, C B, Isenberg, D A, Kalunian, K C, Sanchez-Guerrero, J, Fortin, P R, Maddison, P, Jacobsen, S, Clarke, A E, Werth, V P, Bruce, I N, Buyon, J P, Bernatsky, S, Nived, O, Manzi, S, Hanly, J G, Zoma, A, Merrill, JT, Urowitz, M B, Bae, S-C, Gladman, D D, Truedsson, L, Ruiz-Irastorza, G, and Alarcón, G S

Subjects
immune system diseases, chemical and pharmacologic phenomena, skin and connective tissue diseases
Abstract

Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs. rheumatic disease controls) and the association with SLE manifestations in an international multi-center study.

Published
2015
Full Text
View/download PDF

16. Breast cancer in systemic lupus

Author

Bernatsky, S, primary, Ramsey-Goldman, R, additional, Petri, M, additional, Urowitz, M B, additional, Gladman, D D, additional, Fortin, P F, additional, Ginzler, E, additional, Romero-Diaz, J, additional, Peschken, C, additional, Jacobsen, S, additional, Hanly, J G, additional, Gordon, C, additional, Nived, O, additional, Yelin, E H, additional, Isenberg, D, additional, Rahman, A, additional, Bae, S-C, additional, Joseph, L, additional, Witte, T, additional, Ruiz-Irastorza, G, additional, Aranow, C, additional, Kamen, D, additional, Sturfeldt, G, additional, Foulkes, W D, additional, Hansen, J E, additional, St Pierre, Y, additional, Raymer, P Chrétien, additional, Tessier-Cloutier, B, additional, and Clarke, A E, additional

Published
2016
Full Text
View/download PDF

20. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort

Author

Urowitz, M B, primary, Gladman, D D, additional, Anderson, N M, additional, Su, J, additional, Romero-Diaz, J, additional, Bae, S C, additional, Fortin, P R, additional, Sanchez-Guerrero, J, additional, Clarke, A, additional, Bernatsky, S, additional, Gordon, C, additional, Hanly, J G, additional, Wallace, D J, additional, Isenberg, D, additional, Rahman, A, additional, Merrill, J, additional, Ginzler, E, additional, Alarcón, G S, additional, Fessler, B F, additional, Petri, M, additional, Bruce, I N, additional, Khamashta, M, additional, Aranow, C, additional, Dooley, M, additional, Manzi, S, additional, Ramsey-Goldman, R, additional, Sturfelt, G, additional, Nived, O, additional, Steinsson, K, additional, Zoma, A, additional, Ruiz-Irastorza, G, additional, Lim, S, additional, Kalunian, K C, additional, Ỉnanç, M, additional, van Vollenhoven, R, additional, Ramos-Casals, M, additional, Kamen, D L, additional, Jacobsen, S, additional, Peschken, C, additional, Askanase, A, additional, and Stoll, T, additional

Published
2016
Full Text
View/download PDF

21. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus

Author

Gordon, C., Kalunian, K., Fessler, B. J., Ramsey-Goldman, R., Mackay, M., Isenberg, D., Khamashta, M., Bruce, I., Gladman, D., Clarke, A., Vasudevan, A., Nived, O., Fortin, P. R., Bae, S.-C., Aranow, C., Sanchez-Guerrero, J., Hanly, J. G., Alarcon, G. S., Petri, M., Steinsson, K., Manzi, S., Rahman, A., Urowitz, M. B., Wallace, D. J., Ruiz-Irastorza, G., Dooley, M. A., Su, L., Bernatsky, S., van Vollenhoven, R., Sturfelt, G., Romero-Dirz, J., and Ramos-Casals, M.

Subjects
immune system diseases, skin and connective tissue diseases
Abstract

Neuropsychiatric (NP) events occur unpredictably in systemic lupus erythematosus (SLE) and most biomarker associations remain to be prospectively validated. We examined a disease inception cohort of 1047 SLE patients to determine which autoantibodies at enrollment predicted subsequent NP events.

Published
2011
Full Text
View/download PDF

22. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus

Author

Ramsey-Goldman, R., Romero-Diaz, J., Jackson, D., Wallace, D. J., Dooley, M. A., Van Vollenhoven, R., Khamashta, M., Isenberg, D., Bae, S. C., Manzi, S., Sturfelt, G., Clarke, A., Bruce, I. N., Fessler, B., Alarcon, G. S., Vasudevan, A., Aranow, C., Rahman, A., Ramos-Casals, M., Fortin, P. R., Bernatsky, S., Hanly, J. G., Petri, M., Steinsson, K., Kalunian, K., Gladman, D. D., Nived, O., Zoma, A., Gordon, C., Merrill, J. T., Urowitz, M. B., and Sanchez-Guerrero, J.

Subjects
sense organs, skin and connective tissue diseases, humanities
Abstract

To examine change in health-related quality of life (HRQoL) in association with clinical outcomes of neuropsychiatric (NP) events in SLE.

Published
2011
Full Text
View/download PDF

23. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

Author

Ramsey-Goldman, R., Romero-Diaz, J., Douglas, J., Khamashta, M., Manzi, S., Nived, O., Zoma, A., Petri, M., Steinsson, K., Kalunian, K., Sanchez-Guerrero, J., Van Vollenhoven, R., Isenberg, D., Gordon, C., Ramos-Casals, M., Bae, S. C., Su, L., Urowitz, M. B., Merrill, J. T., Aranow, C., Dooley, M. A., Clarke, A., Hanly, J. G., Bruce, I. N., Bernatsky, S., Ginzler, E., Wallace, D. J., Sturfelt, G., Rahman, A., Alarcon, G. S., Gladman, D. D., and Fortin, P. R.

Subjects
digestive, oral, and skin physiology
Abstract

To determine the frequency, accrual, attribution and outcome of neuropsychiatric (NP) events and impact on quality of life over 3 years in a large inception cohort of SLE patients.

Published
2010
Full Text
View/download PDF

25. Autoantibodies and Neuropsychiatric events at diagnosis of SLE: Results from an international inception cohort study

Author

Hanly, J. G., Urowitz, M. B., Siannis, F., Farewell, V., Gordon, C., Bae, S.C., Isenberg, D., Dooley, M.A., Clarke, A., Bernatsky, S., Gladman, D., Fortin, P.R., Manzi, S., Steinsson, K., Bruce, I., Ginzler, E., Aranow, C., Wallace, D.J., Ramsey-Goldman, R., Van Vollenhoven, R., Sturfelt, G., Nived, O., Sanchez-Guerrero, J., Alarcón, G.S., Petri, M., Khamashta, M., Zoma, A., Font, J., Kalunian, K., Douglas, J., Qi, Qiufen, and Merrill, J. T.

Subjects
Adult, Male, Ribosomal Proteins, International Cooperation, Lupus Vasculitis, Central Nervous System, Middle Aged, Article, Cohort Studies, Receptors, Glutamate, beta 2-Glycoprotein I, Antibodies, Anticardiolipin, Lupus Coagulation Inhibitor, Humans, Female, Autoantibodies
Abstract

To examine, in an inception cohort of systemic lupus erythematosus (SLE) patients, the association between neuropsychiatric (NP) events and anti-ribosomal P (anti-P), antiphospholipid (lupus anticoagulant [LAC], anticardiolipin), anti-beta2-glycoprotein I, and anti-NR2 glutamate receptor antibodies.NP events were identified using the American College of Rheumatology case definitions and clustered into central/peripheral and diffuse/focal events. Attribution of NP events to SLE was determined using decision rules of differing stringency. Autoantibodies were measured without knowledge of NP events or their attribution.Four hundred twelve patients were studied (87.4% female; mean +/- SD age 34.9 +/- 13.5 years, mean +/- SD disease duration 5.0 +/- 4.2 months). There were 214 NP events in 133 patients (32.3%). The proportion of NP events attributed to SLE varied from 15% to 36%. There was no association between autoantibodies and NP events overall. However, the frequency of anti-P antibodies in patients with central NP events attributed to SLE was 4 of 20 (20%), versus 3 of 107 (2.8%) in patients with other NP events and 24 of 279 (8.6%) in those with no NP events (P = 0.04). Among patients with diffuse NP events, 3 of 11 had anti-P antibodies (27%), compared with 4 of 111 patients with other NP events (3.6%) and 24 of 279 of those with no NP events (8.6%) (P = 0.02). Specific clinical-serologic associations were found between anti-P and psychosis attributed to SLE (P = 0.02) and between LAC and cerebrovascular disease attributed to SLE (P = 0.038). There was no significant association between other autoantibodies and NP events.Clinically distinct NP events attributed to SLE and occurring around the time of diagnosis were found to be associated with anti-P antibodies and LAC. This suggests that there are different autoimmune pathogenetic mechanisms, although low sensitivity limits the clinical application of testing for these antibodies.

Published
2008

26. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: Results from an international inception cohort study

Author

van Vollenhoven, R., Dooley, M. A., Douglas, J., Gordon, C., Zoma, A., Qi, Q., Bruce, I. N., Thompson, K., Steinsson, K., Wallace, D. J., Khamashta, M., Alarcón, G. S., Bae, S. C., Nived, O., Hanly, J. G., Fortin, P. R., Gladman, D., Sanchez-Guerrero, J., Clarke, A., Farewell, V., Sturfelt, G., Isenberg, D., Kalunian, K., Manzi, S., Bernatsky, S., Aranow, C., Urowitz, M. B., Siannis, F., Ginzler, E., Font, J., Ramsey-Goldman, R., and Petri, M.

Subjects
immune system diseases, cardiovascular diseases, skin and connective tissue diseases
Abstract

To examine the association between neuropsychiatric (NP) events with antiphospholipid antibodies (lupus anticoagulant, anticardiolipin), anti-β2 glycoprotein-I, anti-ribosomal P and anti-NR2 glutamate receptor antibodies in an international inception cohort.

Published
2008
Full Text
View/download PDF

27. Breast cancer in systemic lupus.

Author

Bernatsky, S., Ramsey-Goldman, R., Petri, M., Urowitz, M. B., Gladman, D. D., Fortin, P. F., Ginzler, E., Romero-Diaz, J., Peschken, C., Jacobsen, S., Hanly, J. G., Gordon, C., Nived, O., Yelin, E. H., Isenberg, D., Rahman, A., Bae, S.-C., Joseph, L., Witte, T., and Ruiz-Irastorza, G.

Subjects
SYSTEMIC lupus erythematosus treatment, SYSTEMIC lupus erythematosus, BREAST cancer risk factors, DISEASE duration, DEMOGRAPHIC characteristics, GENETICS
Abstract

Objective: There is a decreased breast cancer risk in systemic lupus erythematosus (SLE) versus the general population. We assessed a large sample of SLE patients, evaluating demographic and clinical characteristics and breast cancer risk. Methods: We performed case-cohort analyses within a multi-center international SLE sample. We calculated the breast cancer hazard ratio (HR) in female SLE patients, relative to demographics, reproductive history, family history of breast cancer, and time-dependent measures of anti-dsDNA positivity, cumulative disease activity, and drugs, adjusted for SLE duration. Results: There were 86 SLE breast cancers and 4498 female SLE cancer-free controls. Patients were followed on average for 7.6 years. Versus controls, SLE breast cancer cases tended to be white and older. Breast cancer cases were similar to controls regarding anti-dsDNA positivity, disease activity, and most drug exposures over time. In univariate and multivariate models, the principal factor associated with breast cancers was older age at cohort entry. Conclusions: There was little evidence that breast cancer risk in this SLE sample was strongly driven by any of the clinical factors that we studied. Further search for factors that determine the lower risk of breast cancer in SLE may be warranted. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

28. Treatment pathways in an inception lupus cohort over the first three years.

Author

Hanly, J. G., Sayani, A., Doucette, S., Iczkovitz, S., and Terres, J. A. Ross

Subjects
*SYSTEMIC lupus erythematosus treatment, *ADRENOCORTICAL hormones, *HORMONE therapy, *ANTIMALARIALS, *IMMUNOSUPPRESSIVE agents, *COMBINATION drug therapy, *THERAPEUTICS
Abstract

Objective The treatment algorithm for new onset systemic lupus erythematosus (SLE) is less well defined than for other rheumatic diseases. We examined the treatment patterns in an inception cohort of SLE patients over the first three years of disease between 2000 and 2010. Methods Patients fulfilled the American College of Rheumatology classification criteria for SLE within 12 months of enrollment and completed three subsequent annual visits. Data collection included patient demographics, SLE manifestations, medications, SLE disease activity index-2K (SLEDAI-2K) and Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index. Analysis included descriptive statistics and repeated measures mixed models. Results Seventy-nine patients, 83.5% female and 91.1% Caucasian were studied. At baseline the mean (SD) age was 40.6 (16.4) years, disease duration was 0.36 (0.28) years and SLEDAI-2K was 5.7 (4.6). Over three years, cumulative use of corticosteroids, antimalarials and immunosuppressants was 53.2%, 77.2% and 40.5% respectively. Corticosteroids were usually used in combination with antimalarials and/or immunosuppressants. Between baseline and final assessments the use of corticosteroids fell (44.3% vs 15.2%) in contrast to antimalarials (55.7% vs 70.9%) and immunosuppressants (26.6% vs 34.2%). Of 44/79 (55.7%) patients not receiving corticosteroids at baseline 84.1% remained off corticosteroids for the study duration. Thirty-seven of 79 (46.8%) patients never received corticosteroids and only 5/79 (6.3%) at all four assessments. Patients taking corticosteroids at baseline had higher mean (SD) daily dose and cumulative dose over three years compared with patients not on corticosteroids at baseline (9.0 (0.8) vs 0.3 (1.3) mg; 10.8 (8.5) vs 0.3 (1.2) g). As a group, SLE patients who used corticosteroids either at baseline, at any time in the three year study or in high cumulative doses had the highest average disease activity scores over the same time frame and had a significant fall in SLEDAI-2K scores (p < 0.05) compared with patients not exposed to corticosteroids. Conclusion Use of corticosteroids occurred in approximately half of new onset SLE, usually in combination with antimalarials and/or immunosuppressants. It was associated with both higher disease activity at baseline and improvement over time. Patients who did not receive corticosteroids at presentation were unlikely to do so over the next three years. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

30. Changes in Quality of Life in the First 5 Years of Disease in a Multicenter Cohort of Patients With Systemic Lupus Erythematosus

Author

Urowitz, M., primary, Gladman, D. D., additional, Ibañez, D., additional, Sanchez-Guerrero, J., additional, Bae, S. C., additional, Gordon, C., additional, Fortin, P. R., additional, Clarke, A., additional, Bernatsky, S., additional, Hanly, J. G., additional, Wallace, D. J., additional, Isenberg, D., additional, Rahman, A., additional, Merrill, J., additional, Ginzler, E., additional, Alarcón, G. S., additional, Fessler, B., additional, Khamashta, M., additional, Steinsson, K., additional, Petri, M., additional, Dooley, M., additional, Bruce, I. N., additional, Manzi, S., additional, Sturfelt, G., additional, Nived, O., additional, Ramsey-Goldman, R., additional, Zoma, A., additional, Maddison, P., additional, Kalunian, K., additional, van Vollenhoven, R., additional, Aranow, C., additional, Romero Diaz, J., additional, and Stoll, T., additional

Published
2014
Full Text
View/download PDF

31. Anti-C1q antibodies in systemic lupus erythematosus

Author

Orbai, A-M, primary, Truedsson, L, additional, Sturfelt, G, additional, Nived, O, additional, Fang, H, additional, Alarcón, G S, additional, Gordon, C, additional, Merrill, JT, additional, Fortin, P R, additional, Bruce, I N, additional, Isenberg, D A, additional, Wallace, D J, additional, Ramsey-Goldman, R, additional, Bae, S-C, additional, Hanly, J G, additional, Sanchez-Guerrero, J, additional, Clarke, A E, additional, Aranow, C B, additional, Manzi, S, additional, Urowitz, M B, additional, Gladman, D D, additional, Kalunian, K C, additional, Costner, M I, additional, Werth, V P, additional, Zoma, A, additional, Bernatsky, S, additional, Ruiz-Irastorza, G, additional, Khamashta, M A, additional, Jacobsen, S, additional, Buyon, J P, additional, Maddison, P, additional, Dooley, M A, additional, Van Vollenhoven, R F, additional, Ginzler, E, additional, Stoll, T, additional, Peschken, C, additional, Jorizzo, J L, additional, Callen, J P, additional, Lim, S S, additional, Fessler, B J, additional, Inanc, M, additional, Kamen, D L, additional, Rahman, A, additional, Steinsson, K, additional, Franks, A G, additional, Sigler, L, additional, Hameed, S, additional, Pham, N, additional, Brey, R, additional, Weisman, M H, additional, McGwin, G, additional, Magder, L S, additional, and Petri, M, additional

Published
2014
Full Text
View/download PDF

33. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort

Author

Urowitz, M. B., primary, Gladman, D. D., additional, Ibañez, D., additional, Fortin, P. R., additional, Bae, S. C., additional, Gordon, C., additional, Clarke, A., additional, Bernatsky, S., additional, Hanly, J. G., additional, Isenberg, D., additional, Rahman, A., additional, Sanchez‐Guerrero, J., additional, Wallace, D. J., additional, Ginzler, E., additional, Alarcón, G. S., additional, Merrill, J. T., additional, Bruce, I. N., additional, Sturfelt, G., additional, Nived, O., additional, Steinsson, K., additional, Khamashta, M., additional, Petri, M., additional, Manzi, S., additional, Ramsey‐Goldman, R., additional, Dooley, M. A., additional, van Vollenhoven, R. F., additional, Ramos, M., additional, Stoll, T., additional, Zoma, A., additional, Kalunian, K., additional, and Aranow, C., additional

Published
2011
Full Text
View/download PDF

34. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA

Author

Isenberg, D. A., primary, Allen, E., additional, Farewell, V., additional, D'Cruz, D., additional, Alarcon, G. S., additional, Aranow, C., additional, Bruce, I. N., additional, Dooley, M. A., additional, Fortin, P. R., additional, Ginzler, E. M., additional, Gladman, D. D., additional, Hanly, J. G., additional, Inanc, M., additional, Kalunian, K., additional, Khamashta, M., additional, Merrill, J. T., additional, Nived, O., additional, Petri, M., additional, Ramsey-Goldman, R., additional, Sturfelt, G., additional, Urowitz, M., additional, Wallace, D. J., additional, Gordon, C., additional, and Rahman, A., additional

Published
2010
Full Text
View/download PDF

35. Surveillance of systemic autoimmune rheumatic diseases using administrative data

Author

Bernatsky, S., primary, Lix, L., additional, Hanly, J. G., additional, Hudson, M., additional, Badley, E., additional, Peschken, C., additional, Pineau, C. A., additional, Clarke, A. E., additional, Fortin, P. R., additional, Smith, M., additional, Bélisle, P., additional, Lagace, C., additional, Bergeron, L., additional, and Joseph, L., additional

Published
2010
Full Text
View/download PDF

36. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus

Author

Hanly, J G, primary, Urowitz, M B, additional, Su, L, additional, Bae, S C, additional, Gordon, C, additional, Wallace, D J, additional, Clarke, A, additional, Bernatsky, S, additional, Isenberg, D, additional, Rahman, A, additional, Alarcón, G S, additional, Gladman, D D, additional, Fortin, P R, additional, Sanchez-Guerrero, J, additional, Romero-Diaz, J, additional, Merrill, J T, additional, Ginzler, E, additional, Bruce, I N, additional, Steinsson, K, additional, Khamashta, M, additional, Petri, M, additional, Manzi, S, additional, Dooley, M A, additional, Ramsey-Goldman, R, additional, Van Vollenhoven, R, additional, Nived, O, additional, Sturfelt, G, additional, Aranow, C, additional, Kalunian, K, additional, Ramos-Casals, M, additional, Zoma, A, additional, Douglas, J, additional, Thompson, K, additional, and Farewell, V, additional

Published
2009
Full Text
View/download PDF

37. Anti-C1q antibodies in systemic lupus erythematosus.

Author

Orbai, A-M, Truedsson, L, Sturfelt, G, Nived, O, Fang, H, Alarcón, G S, Gordon, C, Merrill, JT, Fortin, P R, Bruce, I N, Isenberg, D A, Wallace, D J, Ramsey-Goldman, R, Bae, S-C, Hanly, J G, Sanchez-Guerrero, J, Clarke, A E, Aranow, C B, Manzi, S, and Urowitz, M B

Subjects
IMMUNOGLOBULINS, SYSTEMIC lupus erythematosus, LUPUS nephritis, ASIANS, SEROLOGY, PATIENTS, DISEASES
Abstract

The article discusses the study which highlights the connection between anti-C1q antibodies with systemic lupus erythematosus (SLE) and lupus nephritis. It states that Anti-C1q was common with patients with SLE and people of Asian ethnicity. It mentions the association of anti-C1q with renal involvement, independent of demographics and other serologies.

Published
2015
Full Text
View/download PDF

38. Mortality related to cerebrovascular disease in systemic lupus erythematosus

Author

Bernatsky, S, primary, Clarke, A, additional, Gladman, D D, additional, Urowitz, M, additional, Fortin, P R, additional, Barr, S G, additional, Senécal, J-L, additional, Zummer, M, additional, Edworthy, S, additional, Sibley, J, additional, Pope, J, additional, Ensworth, S, additional, Ramsey-Goldman, R, additional, and Hanly, J G, additional

Published
2006
Full Text
View/download PDF

47. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort.

Author

Urowitz, M. B., Gladman, D. D., Ibañez, D., Fortin, P. R., Bae, S. C., Gordon, C., Clarke, A., Bernatsky, S., Hanly, J. G., Isenberg, D., Rahman, A., Sanchez-Guerrero, J., Wallace, D. J., Ginzler, E., Alarcón, G. S., Merrill, J. T., Bruce, I. N., Sturfelt, G., Nived, O., and Steinsson, K.

Abstract

Objective We describe disease activity, damage, and the accrual of key autoantibodies in an inception systemic lupus erythematosus (SLE) cohort. Methods The Systemic Lupus International Collaborating Clinics (SLICC) International Research Network, comprising 27 centers from 11 countries, has followed an inception cohort of SLE patients yearly according to a standardized protocol. Of these patients, 298 were followed for a minimum of 5 years and constitute the study population. Disease activity was assessed using the SLE Disease Activity Index 2000 (SLEDAI-2K) and damage was assessed using the SLICC/American College of Rheumatology Damage Index (SDI). Antinuclear antibody (ANA), anti-DNA, and anticardiolipin antibody (aCL) levels and lupus anticoagulant were assessed yearly. Descriptive statistics were generated and repeated-measures general linear models were used to evaluate SLEDAI-2K and SDI over time between whites and nonwhites. Results Of the 298 patients, 87% were women, 55% were white, 12% were African American, 14% were Asian, 16% were Hispanic, and 2% were categorized as 'other.' At enrollment, the mean age was 35.3 years, the mean SLEDAI-2K score was 5.9, and the mean disease duration was 5.5 months. Mean SLEDAI-2K scores decreased in the first year and then remained low. SLEDAI-2K scores were significantly lower at each year in whites compared to nonwhites. Mean SDI scores increased progressively over 5 years; there was no significant difference between whites and nonwhites. As expected, ANA positivity was high and anti-DNA positivity was relatively low at enrollment, and both increased over 5 years. Although lupus anticoagulant increased slightly over 5 years, aCL positivity did not. Conclusion Disease activity in newly diagnosed patients decreases over their first 5 years, while damage increases. Antibody positivity ran variable courses over this period. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

48. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity.

Author

Ippolito, A., Wallace, D. J., Gladman, D., Fortin, P. R., Urowitz, M., Werth, V., Costner, M., Gordon, C., Alarcón, G. S., Ramsey-Goldman, R., Maddison, P., Clarke, A., Bernatsky, S., Manzi, S., Bae, S.-C., Merrill, J. T., Ginzler, E., Hanly, J. G., Nived, O., and Sturfelt, G.

Subjects
SYSTEMIC lupus erythematosus, PHOSPHOLIPID antibodies, DNA antibodies, ENZYME-linked immunosorbent assay, CLINICAL pathology, CLINICAL trials, PATIENTS
Abstract

Systemic lupus erythematosus (SLE) is characterized by multiple autoantibodies and complement activation. Recent studies have suggested that anti-nuclear antibody (ANA) positivity may disappear over time in some SLE patients. Anti-double-stranded DNA (dsDNA) antibody titers and complement levels may vary with time and immunosuppressive treatment, while the behavior of anti-extractable nuclear antigen (ENA) over time is less well understood. This study sought to determine the correlation between historical autoantibody tests and current testing in patients with SLE. Three hundred and two SLE patients from the ACR Reclassification of SLE (AROSE) database with both historical and current laboratory data were selected for analysis. The historical laboratory data were compared with the current autoantibody tests done at the reference laboratory and tested for agreement using percent agreement and Kappa statistic. Serologic tests included ANA, anti-dsDNA, anti-Smith, anti-ribonucleoprotein (RNP), anti-Ro, anti-La, rheumatoid factor (RF), C3 and C4. Among those historically negative for immunologic markers, a current assessment of the markers by the reference laboratory generally yielded a low percentage of additional positives (3—13%). However, 6/11 (55%) of those historically negative for ANA were positive by the reference laboratory, and the reference laboratory test also identified 20% more patients with anti-RNP and 18% more with RF. Among those historically positive for immunologic markers, the reference laboratory results were generally positive on the same laboratory test (range 57% to 97%). However, among those with a history of low C3 or C4, the current reference laboratory results indicated low C3 or C4 a low percentage of the time (18% and 39%, respectively). ANA positivity remained positive over time, in contrast to previous studies. Anti-Ro, La, RNP, Smith and anti-dsDNA antibodies had substantial agreement over time, while complement had less agreement. This variation could partially be explained by variability of the historical assays, which were done by local laboratories over varying periods of time. Variation in the results for complement, however, is more likely to be explained by response to treatment. These findings deserve consideration in the context of diagnosis and enrolment in clinical trials. [ABSTRACT FROM AUTHOR]

Published
2011
Full Text
View/download PDF

49. EDITORIAL: The neuropsychiatric SLE SLICC inception cohort study.

Author

Hanly, J. G.

Subjects
*RHEUMATOLOGY, *NEUROPSYCHIATRY, *SYSTEMIC lupus erythematosus, *AUTOIMMUNE diseases, *IMMUNOGLOBULINS, *CLINICAL trials
Abstract

The author comments on the conducted neuropsychiatric (NP) for systemic lupus erythematosus (SLE) systemic lupus international collaborating clinics (SLICC). In the study, SLE has been established with an standardized approach to the diagnosis, classification and attribution of all NP. It finds that autoantibodies are historically relevant to NPSLE with different autoimmune pathogenic mechanisms in the course of the disease.

Published
2008
Full Text
View/download PDF

50. Short-Term Outcome of Neuropsychiatric Events in Systemic Lupus Erythematosus Upon Enrollment into an International Inception Cohort Study.

Author

Hanly, J. G., Urowitz, M. B., Su, L., Sanchez-Guerrero, J., Bae, S. C., Gordon, C., Wallace, D. J., Isenberg, D., Alarcón, G. S., Merrill, J. T., Clarke, A., Bernatsky, S., Dooley, M. A., Fortin, P. R., Gladman, D., Steinsson, K., Petri, M., Bruce, I. N., Manzi, S., and Khamashta, M.

Subjects
*HEALTH outcome assessment, *NEUROPSYCHIATRY, *SYSTEMIC lupus erythematosus, *EVALUATION of medical care, *PHYSICIAN-patient relations, *PATIENTS
Abstract

The article discusses a study which aims to determine the short-term outcome of neuropsychiatric (NP) events of patients with systemic lupus erythematosus (SLE) upon enrollment into an international inception cohort study. Patient-derived mental component summary (MCS) scores were lower in patients with NP events according to the study. Results suggest that there was a significant association between physician outcome scores and patient MCS scores only for NP events attributed to SLE.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results